Cargando…

Epidermal Growth Factor Receptor Expression in Triple Negative and Nontriple Negative Breast Carcinomas

INTRODUCTION: The panel of markers used for molecular classification include estrogen receptors (ER), progesterone receptors (PR), human epidermal growth factor receptor (HER)-2/neu, p53, Bcl-2 and basal markers like cytokeratin 5/6 or epidermal growth factor receptor (EGFR). Among these, EGFR plays...

Descripción completa

Detalles Bibliográficos
Autores principales: Changavi, Arathi A, Shashikala, Arundhathi, Ramji, Ashwini S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559633/
https://www.ncbi.nlm.nih.gov/pubmed/26417156
http://dx.doi.org/10.4103/0974-2727.163129
_version_ 1782388807690092544
author Changavi, Arathi A
Shashikala, Arundhathi
Ramji, Ashwini S
author_facet Changavi, Arathi A
Shashikala, Arundhathi
Ramji, Ashwini S
author_sort Changavi, Arathi A
collection PubMed
description INTRODUCTION: The panel of markers used for molecular classification include estrogen receptors (ER), progesterone receptors (PR), human epidermal growth factor receptor (HER)-2/neu, p53, Bcl-2 and basal markers like cytokeratin 5/6 or epidermal growth factor receptor (EGFR). Among these, EGFR plays an important role and is associated with bad prognosis. AIMS AND OBJECTIVES: To study EGFR expression in triple negative breast carcinoma (TNBC) and non-TNBCs (NTNBCs). MATERIALS AND METHODS: Fifty cases of breast carcinomas were classified and graded according to World Health Organization and Nottingham modification of Scarff-Bloom-Richardson (SBR) system, respectively. The age of the patients ranged from 28 to 69 years. Histological features such as necrosis, pushing borders, lymphocytic infiltrate and periductal elastosis were noted. The panel of markers used in our study included ER, PR, HER-2/neu and EGFR. EGFR expression was assessed based on membrane staining. Chi-square test was applied for statistical analysis to compare EGFR expression with hormonal status and prognostic factors. P < 0.05 was considered significant. RESULTS: The mean age was 49.8 ± 7.2 years. There were 44 (88%) infiltrating ductal carcinoma, 3 (6%) medullary carcinoma and 3 (6%) mucinous carcinoma. EGFR expression was common in young patients and was predominant in TNBC (89.47%), was also expressed in few cases of NTNBC. There was a positive correlation of EGFR expression (P = 0.03491) with a high grade. Medullary carcinomas were triple negative and strongly expressed EGFR. EGFR expression was inversely associated with ER status and showed strong association with necrosis and lymphocytic infiltrate, but not with pushing border and periductal elastosis. CONCLUSION: EGFR is an important marker to stratify patients with breast cancer according to molecular classification. Its expression correlated positively with young age, higher SBR grade, necrosis, lymphocytic infiltrate and inversely with hormonal receptor expression.
format Online
Article
Text
id pubmed-4559633
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-45596332015-09-28 Epidermal Growth Factor Receptor Expression in Triple Negative and Nontriple Negative Breast Carcinomas Changavi, Arathi A Shashikala, Arundhathi Ramji, Ashwini S J Lab Physicians Original Article INTRODUCTION: The panel of markers used for molecular classification include estrogen receptors (ER), progesterone receptors (PR), human epidermal growth factor receptor (HER)-2/neu, p53, Bcl-2 and basal markers like cytokeratin 5/6 or epidermal growth factor receptor (EGFR). Among these, EGFR plays an important role and is associated with bad prognosis. AIMS AND OBJECTIVES: To study EGFR expression in triple negative breast carcinoma (TNBC) and non-TNBCs (NTNBCs). MATERIALS AND METHODS: Fifty cases of breast carcinomas were classified and graded according to World Health Organization and Nottingham modification of Scarff-Bloom-Richardson (SBR) system, respectively. The age of the patients ranged from 28 to 69 years. Histological features such as necrosis, pushing borders, lymphocytic infiltrate and periductal elastosis were noted. The panel of markers used in our study included ER, PR, HER-2/neu and EGFR. EGFR expression was assessed based on membrane staining. Chi-square test was applied for statistical analysis to compare EGFR expression with hormonal status and prognostic factors. P < 0.05 was considered significant. RESULTS: The mean age was 49.8 ± 7.2 years. There were 44 (88%) infiltrating ductal carcinoma, 3 (6%) medullary carcinoma and 3 (6%) mucinous carcinoma. EGFR expression was common in young patients and was predominant in TNBC (89.47%), was also expressed in few cases of NTNBC. There was a positive correlation of EGFR expression (P = 0.03491) with a high grade. Medullary carcinomas were triple negative and strongly expressed EGFR. EGFR expression was inversely associated with ER status and showed strong association with necrosis and lymphocytic infiltrate, but not with pushing border and periductal elastosis. CONCLUSION: EGFR is an important marker to stratify patients with breast cancer according to molecular classification. Its expression correlated positively with young age, higher SBR grade, necrosis, lymphocytic infiltrate and inversely with hormonal receptor expression. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4559633/ /pubmed/26417156 http://dx.doi.org/10.4103/0974-2727.163129 Text en Copyright: © Journal of Laboratory Physicians http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Changavi, Arathi A
Shashikala, Arundhathi
Ramji, Ashwini S
Epidermal Growth Factor Receptor Expression in Triple Negative and Nontriple Negative Breast Carcinomas
title Epidermal Growth Factor Receptor Expression in Triple Negative and Nontriple Negative Breast Carcinomas
title_full Epidermal Growth Factor Receptor Expression in Triple Negative and Nontriple Negative Breast Carcinomas
title_fullStr Epidermal Growth Factor Receptor Expression in Triple Negative and Nontriple Negative Breast Carcinomas
title_full_unstemmed Epidermal Growth Factor Receptor Expression in Triple Negative and Nontriple Negative Breast Carcinomas
title_short Epidermal Growth Factor Receptor Expression in Triple Negative and Nontriple Negative Breast Carcinomas
title_sort epidermal growth factor receptor expression in triple negative and nontriple negative breast carcinomas
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559633/
https://www.ncbi.nlm.nih.gov/pubmed/26417156
http://dx.doi.org/10.4103/0974-2727.163129
work_keys_str_mv AT changaviarathia epidermalgrowthfactorreceptorexpressionintriplenegativeandnontriplenegativebreastcarcinomas
AT shashikalaarundhathi epidermalgrowthfactorreceptorexpressionintriplenegativeandnontriplenegativebreastcarcinomas
AT ramjiashwinis epidermalgrowthfactorreceptorexpressionintriplenegativeandnontriplenegativebreastcarcinomas